Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17028849rdf:typepubmed:Citationlld:pubmed
pubmed-article:17028849lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:17028849lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:17028849lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:17028849lifeskim:mentionsumls-concept:C0599278lld:lifeskim
pubmed-article:17028849pubmed:issue2lld:pubmed
pubmed-article:17028849pubmed:dateCreated2006-10-30lld:pubmed
pubmed-article:17028849pubmed:abstractTextWe have compared the ability of three radioligands, [(125)I]-cyanopindolol, [(3)H]-CGP 12,177 and [(3)H]-dihydroalprenolol, to label the three human beta-adrenoceptor subtypes. Saturation and competition binding experiments were performed using membrane preparations from Chinese hamster ovary cells stably transfected with the three subtypes. While [(3)H]-CGP 12,177 had very similar affinity for beta(1)- and beta(2)-adrenoceptors (about 40 pM), [(125)I]-cyanopindolol and [(3)H]-dihydroalprenolol had 4- to 6-fold higher affinity for beta(2)- as compared to beta(1)-adrenoceptors (10 vs 45 and 187 vs 1,021 pM, respectively). The affinity of [(125)I]-cyanopindolol at beta(3)-adrenoceptors was considerably lower (440 pM) than at the other two subtypes. The beta(3)-adrenoceptor affinity of [(3)H]-CGP 12,177 and [(3)H]-dihydroalprenolol was so low that it could not be estimated within the tested range of radioligand concentrations (up to 4,000 pM and 30,000 pM for [(3)H]-CGP 12,177 and [(3)H]-dihydroalprenolol, respectively). We conclude that all three radioligands are ill-suited to label beta(3)-adrenoceptors, particularly in preparations co-expressing multiple subtypes. In the absence of alternatives, [(125)I]-cyanopindolol appears the least unsuitable to label beta(3)-adrenoceptors. There is a need for high-affinity radioligands which are either selective for beta(3)-adrenoceptors or reasonably non-selective among all three beta-adrenoceptor subtypes.lld:pubmed
pubmed-article:17028849pubmed:languageenglld:pubmed
pubmed-article:17028849pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:citationSubsetIMlld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17028849pubmed:statusMEDLINElld:pubmed
pubmed-article:17028849pubmed:monthNovlld:pubmed
pubmed-article:17028849pubmed:issn0028-1298lld:pubmed
pubmed-article:17028849pubmed:authorpubmed-author:AlewijnseAstr...lld:pubmed
pubmed-article:17028849pubmed:authorpubmed-author:MichelMartin...lld:pubmed
pubmed-article:17028849pubmed:authorpubmed-author:Michel-ReherM...lld:pubmed
pubmed-article:17028849pubmed:authorpubmed-author:NiclaussNadja...lld:pubmed
pubmed-article:17028849pubmed:issnTypePrintlld:pubmed
pubmed-article:17028849pubmed:volume374lld:pubmed
pubmed-article:17028849pubmed:ownerNLMlld:pubmed
pubmed-article:17028849pubmed:authorsCompleteYlld:pubmed
pubmed-article:17028849pubmed:pagination99-105lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:meshHeadingpubmed-meshheading:17028849...lld:pubmed
pubmed-article:17028849pubmed:year2006lld:pubmed
pubmed-article:17028849pubmed:articleTitleComparison of three radioligands for the labelling of human beta-adrenoceptor subtypes.lld:pubmed
pubmed-article:17028849pubmed:affiliationDepartment Pharmacology and Pharmacotherapy, Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, The Netherlands.lld:pubmed
pubmed-article:17028849pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17028849pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17028849lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17028849lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17028849lld:pubmed